PRLD Prelude Therapeutics Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1678660 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY105.4%
TTM net income YoY52.3%
TTM EPS YoY59.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-283.9%
Net margin-247.1%
FCF margin-129.6%
EBITDA margin-277.0%
Returns
ROE-58.4%
ROA-39.5%
ROIC (approx.)-86.6%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets29.3%
Debt / equity0.00x
Current ratio4.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-18.8%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $12.14M | $7.00M | — | — | — |
| R&D expense | $94.30M | $118.00M | $103.39M | $92.89M | $86.78M |
| SG&A expense | $22.41M | $28.72M | $28.88M | $30.65M | $26.96M |
| Operating income | -$104.57M | -$139.71M | -$132.28M | -$123.54M | -$113.73M |
| Pretax income | -$99.50M | -$127.20M | — | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$99.50M | -$127.17M | -$121.83M | -$115.44M | -$111.69M |
| EBITDA | -$102.86M | -$137.94M | -$131.11M | -$122.22M | -$112.82M |
| EPS (basic) | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 |
| EPS (diluted) | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 |
| Weighted avg. shares (diluted) | 76.96M | 75.81M | 60.36M | 47.37M | 46.05M |
| Balance sheet | |||||
| Cash & equivalents | $35.26M | $12.47M | $25.29M | $30.61M | $31.83M |
| Short-term investments | $67.96M | $121.14M | $207.64M | $171.12M | $259.40M |
| Current assets | $105.69M | $135.90M | $235.59M | $204.38M | $295.12M |
| PP&E, net | $5.11M | $6.77M | $7.33M | $4.91M | $3.93M |
| Total assets | $141.31M | $175.51M | $277.67M | $220.50M | $305.10M |
| Current liabilities | $52.99M | $25.64M | $21.83M | $21.70M | $19.20M |
| Total liabilities | $72.68M | $44.06M | $40.58M | $25.06M | $19.20M |
| Shareholders' equity | $68.64M | $131.46M | $237.09M | $195.44M | $285.90M |
| Cash flow statement | |||||
| Operating cash flow | -$56.30M | -$102.89M | -$107.06M | -$83.73M | -$83.53M |
| Capital expenditure | $67,000 | $764,000 | $3.51M | $3.02M | $2.32M |
| Free cash flow | -$56.37M | -$103.65M | -$110.58M | -$86.75M | -$85.85M |
| Investing cash flow | $53.46M | $90.19M | -$34.65M | $81.69M | -$263.80M |
| Financing cash flow | $24.82M | -$120,000 | $136.40M | $815,000 | $164.90M |
| Depreciation & amortization | $1.71M | $1.77M | $1.17M | $1.32M | $915,000 |
| Stock-based compensation | $11.91M | $21.34M | $25.62M | $25.14M | $20.93M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.